APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring

APONTIS PHARMA AG has announced its financial results for 2023, revealing a total sales of EUR 37.0 million surpassing its revised forecast of EUR 36.1 million. The year brought challenges, resulting in a decline from the previous year's sales of EUR 55.7 million. The company faced hurdles, particularly in its Single Pill combination business due to tenders and supply issues. Nevertheless, APONTIS PHARMA managed a better-than-anticipated EBITDA, at EUR -7.7 million before restructuring costs against a forecasted EUR -8.6 million. The year also saw restructuring expenses of EUR 5.6 million.

For the 2024 fiscal year, the company is optimistic, forecasting sales to rise to EUR 41.7 million and expecting a positive EBITDA of EUR 1.8 million. This outlook is supported by newly launched marketing strategies and the expansion of its Single Pill combination portfolio. The anticipated recovery and growth underscore APONTIS PHARMA’s adaptability and strategic planning in navigating challenges and setting a course for profitability.

Bruno Wohlschlegel, CEO, highlighted the impact of the performance and efficiency improvement program initiated in 2023. Despite downturns, he expressed confidence in the company's market leadership and its potential for growth in Single Pill combinations. The streamlined operations and focused marketing efforts are set to drive the company’s return to profitable growth.

In the face of financial adversity, APONTIS PHARMA's resolve to innovate and adapt promises positioning for future success. With strategic product launches and improved operational efficiencies, the company aims to reclaim and surpass its former financial health in the coming year.